MediWound (NASDAQ:MDWD) Coverage Initiated by Analysts at Alliance Global Partners

Alliance Global Partners assumed coverage on shares of MediWound (NASDAQ:MDWD - Free Report) in a research report sent to investors on Friday, MarketBeat reports. The firm issued a buy rating and a $25.00 price objective on the biopharmaceutical company's stock.

A number of other brokerages have also commented on MDWD. StockNews.com upgraded shares of MediWound to a "sell" rating in a research note on Friday, March 21st. HC Wainwright reiterated a "buy" rating and set a $25.00 price target on shares of MediWound in a research note on Thursday, March 20th. Finally, Craig Hallum initiated coverage on MediWound in a research note on Friday, February 28th. They issued a "buy" rating and a $39.00 price objective for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.75.

MediWound Stock Performance

Shares of MediWound stock traded up $0.46 on Friday, reaching $17.71. 28,770 shares of the company's stock were exchanged, compared to its average volume of 88,344. The firm's 50-day moving average is $16.86 and its two-hundred day moving average is $17.46. The company has a market capitalization of $191.41 million, a P/E ratio of -6.11 and a beta of 0.50. MediWound has a 52 week low of $12.78 and a 52 week high of $24.00.

MediWound (NASDAQ:MDWD - Get Free Report) last released its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.23. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The company had revenue of $5.84 million for the quarter, compared to analysts' expectations of $5.79 million. During the same quarter in the prior year, the firm earned ($0.19) EPS. On average, analysts expect that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. R Squared Ltd purchased a new position in shares of MediWound during the 4th quarter valued at $32,000. GAMMA Investing LLC lifted its holdings in shares of MediWound by 1,507.1% in the 1st quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 1,703 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,162 shares during the period. Bank of America Corp DE boosted its position in MediWound by 38.0% during the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company's stock valued at $141,000 after buying an additional 2,178 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of MediWound by 7.3% during the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after buying an additional 739 shares during the period. Hedge funds and other institutional investors own 46.83% of the company's stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.